Kinoxis snares $266 million for psychiatric drug
University of Sydney spin out company Kinoxis Therapeutics has turned R&D into novel therapeutics for social dysfunction and substance use disorders into a $266 million windfall. The company has entered into a strategic partnership and licensing agreement with pharmaceutical company, Boehringer Ingelheim to develop novel treatments for psychiatric patients with social dysfunction symptoms. Kinoxis’ lead…
Details